12-Month Post-Discharge Liver Function Test Abnormalities Among Patients With COVID-19: A Single-Center Prospective Cohort Study

The longitudinal effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the liver are unknown. This study aimed to characterize dynamic changes in liver function test abnormalities in patients with COVID-19 at the acute phase and recovery phase. A prospective cohort stu...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in cellular and infection microbiology 2022-04, Vol.12, p.864933-864933
Main Authors: Liao, Xuejiao, Li, Dapeng, Ma, Zhenghua, Zhang, Lina, Zheng, Baoqi, Li, Zhiyan, Li, Guobao, Liu, Lei, Zhang, Zheng
Format: Article
Language:English
Subjects:
Aftercare
alanine aminotransferase (ALT)
albumin
aspartate aminotransferase (AST)
Cellular and Infection Microbiology
COVID-19
gamma-glutamyltransferase (GGT)
Humans
Liver Diseases
Liver Function Tests
Patient Discharge
Prospective Studies
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The longitudinal effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the liver are unknown. This study aimed to characterize dynamic changes in liver function test abnormalities in patients with COVID-19 at the acute phase and recovery phase. A prospective cohort study involved patients with COVID-19 who were admitted to Shenzhen Third People's Hospital between January 11, 2020, and April 27, 2020. Patients underwent liver function tests at hospitalization and at the outpatient visit at the 1-month, 3-month, 6-month, and 12-month follow-ups. Among 461 patients, 28.4% of patients had any kind of liver function tests abnormality at admission, manifested as elevated ALT (13.0%), AST (17.6%), and GGT (15.8%) levels. The trajectory analysis indicated a marked improvement in liver function after discharge, with any kind of liver function test abnormalities of 25.1% at 1 month, 13.2% at 3 months, 16.7% at 6 months, and 13.2% at 12 months after discharge. Persistent liver function abnormalities were observed in patients with pre-existing conditions during follow-up. A significantly higher prevalence of ultrasound determined fatty liver disease was found in those patients with more frequent LFT abnormalities at follow-up. In this study of patients with COVID-19, liver damage in COVID-19 was usually temporary and could return to normal at the end of the 12-month follow-up.
ISSN:2235-2988
2235-2988
DOI:10.3389/fcimb.2022.864933